Home Stock

Stock Research: Dr. Reddy's

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Dr. Reddy's

NSI:DRREDDY INE089A01023
76
  • Value
    66
  • Growth
    42
  • Safety
    Safety
    54
  • Combined
    56
  • Sentiment
    78
  • 360° View
    360° View
    76
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. It operates in the pharmaceutical industry, specializing in APIs, generics, branded generics, biosimilars, and OTC pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. In the last fiscal year, the company had a market cap of $12,191 million, profits of $2,558 million, and revenue of $3,820 million, with 26944 employees.

more

ANALYSIS: With an Obermatt 360° View of 76 (better than 76% compared with alternatives) for 2026, overall professional sentiment and financial characteristics for the stock Dr. Reddy's are very positive. The 360° View is based on consolidating four consolidated indicators, with half of the indicators below and half above average for Dr. Reddy's. The consolidated Value Rank has an attractive rank of 66, which means that the share price of Dr. Reddy's is on the lower side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 66% of alternative stocks in the same industry. The company is also safely financed with a Safety rank of 54. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 78. But the consolidated Growth Rank has a low rank of 42, which means that the company is below average in terms of growth and momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. 58 of its competitors have better growth. ...read more

more
Strongest Rank Analyst Opinions
Weakest Rank Pro Holdings
Country India
Industry Pharmaceuticals
Size X-Large
Website drreddys.com
Index
CNX Nifty 50
Dr. Reddy's stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 20-May-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
66 65 63 61
Growth
42 13 31 47
Safety
Safety
54 51 59 47
Sentiment
78 43 84 50
360° View
360° View
76 25 76 47
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
13 21 38 83
Opinions Change
66 10 39 50
Pro Holdings
n/a 54 99 8
Market Pulse
85 88 77 57
Sentiment
78 43 84 50
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
66 65 63 61
Growth
42 13 31 47
Safety Safety
54 51 59 47
Combined
56 21 53 51
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
48 56 62 61
Price vs. Earnings (P/E)
57 75 82 63
Price vs. Book (P/B)
59 57 62 58
Dividend Yield
51 42 37 42
Value
66 65 63 61
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
24 48 17 46
Profit Growth
88 25 51 86
Capital Growth
27 1 46 42
Stock Returns
51 43 67 21
Growth
42 13 31 47
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
51 56 60 44
Refinancing
64 72 74 66
Liquidity
44 46 52 47
Safety Safety
54 51 59 47

Similar Stocks

Discover high‑ranked alternatives to Dr. Reddy's and broaden your portfolio horizons.

Tech Mahindra

NSI:TECHM
Country: India
Industry: IT Consulting & oth. Services
Size: X-Large
Full Stock Analysis

Coal India

NSI:COALINDIA
Country: India
Industry: Coal & Consumable Fuels
Size: XX-Large
Full Stock Analysis

Petronet LNG

NSI:PETRONET
Country: India
Industry: Oil & Gas Transportation
Size: Large
Full Stock Analysis

Cipla

NSI:CIPLA
Country: India
Industry: Pharmaceuticals
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

The stock offers good value, safe financing, and positive sentiment. However, it has below-average growth expectations. It is well-suited for conservative buy-and-hold investors who prioritize stability and low valuation over growth.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews